نتایج جستجو برای: deferoxamine
تعداد نتایج: 2173 فیلتر نتایج به سال:
normal 0 false false false en-us x-none ar-sa microsoftinternetexplorer4 background: thalassemia is an inherited disorder in which repeated blood transfusion is needed. this causes accumulation of iron in various organs. silymarin is a natural medicinal plant that has been used for centuries in the treatment of liver depositions. in this study, magnetic resonance imaging (mri) of liver, which h...
Background: Deferoxamine mesylate is still the conventional and well-known iron chelator for patients with thalassemia major. However, due to some marketing issues the well-known original brand, Desferal®, produced by Novartis Pharmaceuticals Company is not as available as before. The generic brands of Deferoxamine have been introduced in many parts of the world including Iran; however, they ar...
BACKGROUND Oxidative stress and smoking contribute to endothelial dysfunction. Iron might also play a role in oxidative stress generation and endothelial dysfunction. However, the involvement of iron in smoking-induced endothelial dysfunction in healthy smokers remains unclear. Therefore, we examined here whether (1) intravenous iron infusion impaired endothelial function evaluated by flow-medi...
background: tissue iron deposition may disturb functions of the organs. in many diseases like thalassemia, the patients suffer from iron deposition in kidney and heart tissues. deferoxamine (df) is a synthetic iron chelator and silymarin (sm) is an antioxidant and also a candidate for iron chelating. this study was designed to investigate the effect of df and sm combination against kidney and h...
Ischemia-reperfusion reduces the negative functional effects of cyclic GMP in cardiac myocytes. In this study, we tested the hypothesis that upregulation of hypoxic inducible factor-1 (HIF-1) would improve the actions of cyclic GMP signaling following simulated ischemia-reperfusion. HIF-1 alpha was increased with deferoxamine (150 mg/kg for 2 days). Rabbit cardiac myocytes were subjected to sim...
BACKGROUND AND PURPOSE It has been shown that 3 days of 62 mg/kg/day deferoxamine infusion (maximum dose not to exceed 6000 mg/day) is safe and tolerated by intracerebral hemorrhage (ICH) patients. The aim of this study was to investigate the efficacy of deferoxamine mesylate for edema resolution and hematoma absorption after ICH. METHODS From February 2013 to May 2014, spontaneous ICH patien...
It has been proposed that alterations in intracellular calcium homeostasis mediate the genesis of lethal cell injury with an acute oxidative stress. It is shown here, however, that such changes can be dissociated by two different means from the cell death occurring with the exposure of cultured hepatocytes to hydrogen peroxide generated either in the medium by glucose oxidase or intracellularly...
Before 1987, iron chelation therapy for patients with thalassemia major and other refractory anemias requiring regular transfusions depended almost entirely on one drug, deferoxamine. The drug has dramatically increased survival in patients with thalassemia major in countries where it is readily available.1,2 Although many other compounds had been tried as iron-chelating agents in experiments w...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید